If you or a loved one developed uncontrollable muscle movements after taking Reglan (metoclopramide), you may be facing tardive dyskinesia. The FDA has issued a black box warning about this risk, yet many patients remain unaware. Building on decades of pharmacovigilance research, this page explains what the label warning means, how to recognize symptoms, and why early monitoring matters.
Reglan (metoclopramide) is a medication approved for short-term use in adults with symptomatic gastroesophageal reflux or diabetic gastroparesis. However, its association with tardive dyskinesia (TD), a potentially irreversible movement disorder, has led to significant litigation. For Illinois residents considering a settlement, understanding the statute of limitations and the medical evidence linking Reglan to TD is critical. Tardive dyskinesia is characterized by involuntary, repetitive movements of the face, tongue, trunk, or extremities. The condition can be disfiguring and may persist even after the offending drug is discontinued. According to the FDA-approved labeling, metoclopramide, including Reglan, can cause TD, and the risk increases with longer treatment duration and higher cumulative doses (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The labeling also notes that Reglan may suppress or partially suppress signs of TD, potentially delaying diagnosis (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Clinical presentation typically includes orofacial movements, such as lip smacking, tongue protrusion, or grimacing, as well as choreiform movements of the limbs or trunk. Diagnosis is based on clinical history and examination, often using standardized rating scales like the Abnormal Involuntary Movement Scale (AIMS). The condition can develop after months or years of exposure, but cases have been reported after shorter durations, particularly in vulnerable populations.
Reglan is a dopamine receptor antagonist that increases gastrointestinal motility. Its mechanism of action involves blocking D2 receptors in the chemoreceptor trigger zone and the gut. However, chronic blockade of dopamine receptors in the basal ganglia is believed to lead to supersensitivity of these receptors, contributing to the development of TD. The FDA-approved labeling explicitly warns that Reglan can cause TD and that the risk increases with duration of treatment and total cumulative dosage (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The labeling also states that Reglan is contraindicated in patients with a history of TD and recommends using the drug for the shortest duration necessary, with periodic reassessment of continued need (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). For gastroesophageal reflux, the maximum approved treatment duration is 12 weeks, and for diabetic gastroparesis, treatment should not exceed 12 weeks unless longer use is unavoidable, in which case routine monitoring for TD is advised (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Despite these warnings, many patients were prescribed Reglan for extended periods, sometimes years, without adequate monitoring. The adequacy of warnings regarding Reglan and TD is a central issue in litigation. The boxed warning, added in 2009, states that metoclopramide can cause TD and that the risk increases with duration of treatment and total cumulative dosage (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). However, prior to this update, warnings were less prominent, and many patients and healthcare providers were unaware of the significant risk. The labeling also notes that Reglan is not recommended for pediatric patients due to the risk of TD and other extrapyramidal symptoms (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397).
For affected patients, settlement considerations often depend on the duration of Reglan use, the severity of TD symptoms, and the timeline between exposure and diagnosis. Illinois courts have generally applied a two-year statute of limitations for personal injury claims, starting from the date the injury was discovered or should have been discovered. Given that TD can develop insidiously and may be masked by the drug itself, the discovery date can be complex. Patients who developed TD after long-term Reglan use may have a valid claim if they can demonstrate that the manufacturer failed to provide adequate warnings or that their prescribing physician was not informed of the risks. The timeline between exposure and documented harm is variable. Some patients develop TD within months, while others may not show symptoms until after years of use. The FDA labeling emphasizes that the risk increases with duration of treatment and total cumulative dosage (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Once TD is diagnosed, immediate discontinuation of Reglan is recommended, but the movements may persist indefinitely. For settlement purposes, the severity of TD, its impact on daily functioning, and the patient's age and overall health are considered. Illinois residents should consult with an attorney experienced in pharmaceutical litigation to determine the applicable statute of limitations for their specific case, as the clock may start ticking from the date of diagnosis or from when the patient reasonably should have known that Reglan caused their symptoms. In summary, the medical evidence clearly establishes a causal link between Reglan and TD, with the FDA labeling providing explicit warnings about the risk. For Illinois patients, the statute of limitations for filing a claim is typically two years from discovery of the injury, but individual circumstances may vary. Settlement considerations hinge on the adequacy of warnings, the duration of exposure, and the severity of harm. Patients who developed TD after prolonged Reglan use should seek legal advice promptly to preserve their rights.
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
In Illinois, the statute of limitations for personal injury claims, including those related to Reglan-induced tardive dyskinesia, is generally two years from the date the injury was discovered or reasonably should have been discovered. Because TD can develop slowly and may be masked by the drug, the discovery date can be complex. It is crucial to consult with an attorney experienced in pharmaceutical litigation to determine the applicable deadline for your specific case.
Reglan (metoclopramide) is a dopamine receptor antagonist. Chronic blockade of dopamine receptors in the basal ganglia is believed to lead to supersensitivity of these receptors, contributing to the development of tardive dyskinesia. The FDA-approved labeling explicitly warns that Reglan can cause TD, and the risk increases with longer treatment duration and higher cumulative doses (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397).
Tardive dyskinesia is characterized by involuntary, repetitive movements of the face, tongue, trunk, or extremities. Common symptoms include lip smacking, tongue protrusion, grimacing, and choreiform movements of the limbs or trunk. The condition can be disfiguring and may persist even after the offending drug is discontinued.
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.
Request archival records or inquire about member-exclusive transition and benefit programs.
Individuals with documented archive exposure and a related diagnosis may request an independent, no-cost eligibility review.